Compare INBS & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBS | ALZN |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.1M |
| IPO Year | 2019 | 2021 |
| Metric | INBS | ALZN |
|---|---|---|
| Price | $2.91 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 41.6K | ★ 177.9K |
| Earning Date | 05-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.65 | 22.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,980,484.00 | N/A |
| Revenue This Year | $778.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.51 |
| 52 Week High | $24.90 | $8.22 |
| Indicator | INBS | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 26.16 |
| Support Level | $1.49 | N/A |
| Resistance Level | $7.25 | $2.59 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 0.74 | 5.09 |
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.